Drug Search Results
More Filters [+]

Epalrestat

Alternative Names: epalrestat
Latest Update: 2024-06-03
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: AKR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Bangladesh | China | India | Korea | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: China Resources Zizhu
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Epalrestat

Countries in Clinic: China, United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 3: Congenital Disorders of Glycosylation

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PMM2-CDG

P3

Active, not recruiting

Congenital Disorders of Glycosylation

2025-02-28

66%

CTR20221709

P1

Not yet recruiting

Type 2 Diabetes

None

Recent News Events